Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
Read Now: Expert Opinions on HIV Cure Research
  
  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

U.S. News

FDA Advisory Panel Backs Preventive Use of HIV Drug

May 11, 2012

On Thursday, advisors to the Food and Drug Administration recommended the agency approve the use of Truvada in healthy people who are at high risk for HIV infection.

FDA's advisory panel, composed of 22 outside medical experts, evaluated studies of once-a-day Truvada and heard scientific presentations. Several speakers told the panel better prevention methods besides condoms and counseling are needed to make a dent in the estimated 50,000 new infections that occur in the United States each year. Truvada is not meant to replace these safe-sex measures but to be used with them to enhance protection. The drug is already approved for treating HIV infection.

Many newly infected Americans are men whose sexual partners are unaware of their infection; young black men who have sex with men are at highest risk. Truvada would be prescribed for high-risk groups like MSM with multiple sex partners, people in serodiscordant relationships, and sex workers.

Advertisement
One panelist characterized the expanded use of the HIV drug, which costs around $14,000 a year, as "an amazing opportunity to turn the tide on this epidemic."

However, the advisors struggled with how to ensure healthy people taking Truvada do so safely and effectively. While the medicine would come with specific instructions, including the need for HIV screening before starting the regimen and other lab tests, FDA officials said Thursday there is no practical way to enforce a testing requirement. Further, such a requirement could pose a barrier to use. Some panelists voted "no" or abstained due to a lack of data for Truvada's efficacy in women and African-Americans.

FDA typically follows the guidance of its advisory panels. Agency approval may make it more likely that health insurers would cover the cost of the drug's preventive use.

Back to other news for May 2012

Adapted from:
New York Times
05.11.2012; Denise Grady


  
  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.
 
See Also
FDA Panel Recommends Approval of Truvada as Preventive Treatment for HIV
More News and Research on HIV Medications for HIV Prevention

No comments have been made.
 

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

Your Name:


Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Tools
 

Advertisement